Management of Visual Hallucinations in the Elderly

Initial Diagnostic Workup

The American Geriatrics Society recommends screening the medication list immediately for anticholinergics, steroids, and dopaminergic agents as these are common culprits in elderly patients 1
Assessing for preserved insight is crucial, as it strongly suggests Charles Bonnet Syndrome rather than primary psychiatric illness, according to the American Academy of Neurology 1, 2
Evaluating vision status through formal ophthalmological examination is necessary, as 15-60% of patients with ophthalmologic disorders experience Charles Bonnet Syndrome, as reported by the American Academy of Ophthalmology 1, 3
Ruling out delirium by assessing for altered mental status, fluctuating consciousness, and acute onset is essential, as it is frequently underdiagnosed, especially in hypoactive presentations, according to the Society of Hospital Medicine 2

The American Academy of Neurology recommends non-pharmacological approaches as first-line treatment for Charles Bonnet Syndrome, as there is no significant evidence supporting pharmacological treatment 2
Patient and caregiver education is therapeutic in itself and significantly reduces anxiety about the hallucinations, as suggested by the Alzheimer's Association 2
Refer for vision rehabilitation and optimize any correctable visual impairment, as recommended by the American Academy of Ophthalmology 1
For medication-induced hallucinations, the Journal of the American Geriatrics Society recommends reducing or discontinuing the offending agent under guidance of both sleep specialist and primary care physician 4
Tapering causative medications rather than abrupt discontinuation is necessary when medically appropriate, according to the American Geriatrics Society 4
The American Academy of Neurology recommends rivastigmine as first-line treatment for hallucinations in dementia with Lewy bodies 2
Quetiapine can be considered for refractory cases, starting at low doses, as suggested by the American Psychiatric Association 2

Using validated assessment tools, such as the University of Miami Parkinson's Disease Hallucinations Questionnaire or North-East Visual Hallucination Interview, is necessary for tracking visual hallucinations, as recommended by the International Parkinson and Movement Disorder Society 2
Watching for development of additional neuropsychiatric symptoms suggesting progression of underlying neurodegenerative disease is essential, according to the American Academy of Neurology 2
Reassessing periodically for emergence of delirium, cognitive decline, or loss of insight is necessary, as suggested by the Society of Hospital Medicine 1, 2